

ABSTRACT

The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in a limulus clotting factor protease-like gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression and gene function, and as potential treatments for various disease states and disease conditions.

1. A transgenic animal comprising a mutation in a limulus clotting factor protease-like gene.

2. A transgenic animal comprising a mutation in a limulus clotting factor protease-like gene, wherein the mutation is a deletion.

3. A transgenic animal comprising a mutation in a limulus clotting factor protease-like gene, wherein the mutation is a substitution.

4. A transgenic animal comprising a mutation in a limulus clotting factor protease-like gene, wherein the mutation is a deletion or a substitution.

5. A transgenic animal comprising a mutation in a limulus clotting factor protease-like gene, wherein the mutation is a deletion or a substitution, and wherein the mutation is located in the coding region of the gene.

6. A transgenic animal comprising a mutation in a limulus clotting factor protease-like gene, wherein the mutation is a deletion or a substitution, and wherein the mutation is located in the coding region of the gene, and wherein the mutation is located in the region of the gene that encodes the protease-like domain.

7. A transgenic animal comprising a mutation in a limulus clotting factor protease-like gene, wherein the mutation is a deletion or a substitution, and wherein the mutation is located in the coding region of the gene, and wherein the mutation is located in the region of the gene that encodes the protease-like domain, and wherein the mutation is located in the region of the gene that encodes the protease-like domain.

8. A transgenic animal comprising a mutation in a limulus clotting factor protease-like gene, wherein the mutation is a deletion or a substitution, and wherein the mutation is located in the coding region of the gene, and wherein the mutation is located in the region of the gene that encodes the protease-like domain, and wherein the mutation is located in the region of the gene that encodes the protease-like domain, and wherein the mutation is located in the region of the gene that encodes the protease-like domain.

9. A transgenic animal comprising a mutation in a limulus clotting factor protease-like gene, wherein the mutation is a deletion or a substitution, and wherein the mutation is located in the coding region of the gene, and wherein the mutation is located in the region of the gene that encodes the protease-like domain, and wherein the mutation is located in the region of the gene that encodes the protease-like domain, and wherein the mutation is located in the region of the gene that encodes the protease-like domain, and wherein the mutation is located in the region of the gene that encodes the protease-like domain.

10. A transgenic animal comprising a mutation in a limulus clotting factor protease-like gene, wherein the mutation is a deletion or a substitution, and wherein the mutation is located in the coding region of the gene, and wherein the mutation is located in the region of the gene that encodes the protease-like domain, and wherein the mutation is located in the region of the gene that encodes the protease-like domain, and wherein the mutation is located in the region of the gene that encodes the protease-like domain, and wherein the mutation is located in the region of the gene that encodes the protease-like domain, and wherein the mutation is located in the region of the gene that encodes the protease-like domain.